These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35468945)

  • 1. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
    Pennesi E; Michels N; Brivio E; van der Velden VHJ; Jiang Y; Thano A; Ammerlaan AJC; Boer JM; Beverloo HB; Sleight B; Chen Y; Vormoor-Bürger B; Rives S; Bielorai B; Rössig C; Petit A; Rizzari C; Engstler G; Starý J; Bautista Sirvent FJ; Chen-Santel C; Bruno B; Bertrand Y; Rialland F; Plat G; Reinhardt D; Vinti L; Von Stackelberg A; Locatelli F; Zwaan CM
    Leukemia; 2022 Jun; 36(6):1516-1524. PubMed ID: 35468945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
    Nakayama H; Ogawa C; Sekimizu M; Fujisaki H; Kosaka Y; Hashimoto H; Saito AM; Horibe K
    Int J Hematol; 2022 Oct; 116(4):612-621. PubMed ID: 35635686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
    Rubinstein JD; O'Brien MM
    Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
    O'Brien MM; Ji L; Shah NN; Rheingold SR; Bhojwani D; Yuan CM; Xu X; Yi JS; Harris AC; Brown PA; Borowitz MJ; Militano O; Kairalla J; Devidas M; Raetz EA; Gore L; Loh ML
    J Clin Oncol; 2022 Mar; 40(9):956-967. PubMed ID: 35007127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].
    An LL; Zhao DF; Hou RF; Guan HH; Yan H; Lin YH; Tong CR; Wu T; Liu SY
    Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):911-916. PubMed ID: 38185520
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
    Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
    Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Marks DI; Kebriaei P; Stelljes M; Gökbuget N; Kantarjian H; Advani AS; Merchant A; Stock W; Cassaday RD; Wang T; Zhang H; Loberiza F; Vandendries E; DeAngelo DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1720-1729. PubMed ID: 31039409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22
    Pennesi E; Brivio E; Ammerlaan ACJ; Jiang Y; Van der Velden VHJ; Beverloo HB; Sleight B; Locatelli F; Brethon B; Rossig C; Engstler G; Nilsson A; Bruno B; Petit A; Bielorai B; Rizzari C; Rialland F; Rubio-San-Simón A; Sirvent FJB; Diaz-de-Heredia C; Rives S; Zwaan CM
    Haematologica; 2024 Oct; 109(10):3157-3166. PubMed ID: 38186333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
    Brivio E; Locatelli F; Lopez-Yurda M; Malone A; Díaz-de-Heredia C; Bielorai B; Rossig C; van der Velden VHJ; Ammerlaan ACJ; Thano A; van der Sluis IM; den Boer ML; Chen Y; Sleight B; Brethon B; Nysom K; Sramkova L; Øra I; Vinti L; Chen-Santel C; Zwaan CM
    Blood; 2021 Mar; 137(12):1582-1590. PubMed ID: 33067614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
    Ceolin V; Brivio E; van Tinteren H; Rheingold SR; Leahy A; Vormoor B; O'Brien MM; Rubinstein JD; Kalwak K; De Moerloose B; Jacoby E; Bader P; López-Duarte M; Goemans BF; Locatelli F; Hoogerbrugge P; Calkoen FG; Zwaan CM
    Leukemia; 2023 Jan; 37(1):53-60. PubMed ID: 36310183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
    Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
    JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
    Torrent A; Morgades M; García-Calduch O; de Llano MPQ; Montesinos P; Navarro I; Hernández-Rivas JM; Bárez-García A; González-Campos J; Oiartzabal I; Valero M; Cervera M; Zudaire T; Albors-Ferreiro M; López-Godino O; Gil-Cortés C; Villalón L; Saldaña R; Ribera JM
    Eur J Haematol; 2023 Sep; 111(3):485-490. PubMed ID: 37381686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
    Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
    Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.
    Wu JH; Pennesi E; Bautista F; Garrett M; Fukuhara K; Brivio E; Ammerlaan ACJ; Locatelli F; van der Sluis IM; Rossig C; Chen-Santel C; Bielorai B; Petit A; Starý J; Díaz-de-Heredia C; Rives S; O'Marcaigh A; Rizzari C; Engstler G; Nysom K; Rubio-San-Simón A; Bruno B; Bertrand Y; Brethon B; Rialland F; Plat G; Dirksen U; Sramkova L; Zwaan CM; Huitema ADR
    Clin Pharmacokinet; 2024 Jul; 63(7):981-997. PubMed ID: 38907948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Chen J; Haughey M; Vandendries E; DeAngelo DJ; Kantarjian HM; Ruiz-Garcia A
    Clin Transl Sci; 2021 Jan; 14(1):184-193. PubMed ID: 32812370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
    Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
    Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.